RIPK1 and myeloid sarcoma: Aberrant activation of the receptor-interacting protein kinase 1 (RIPK1) signaling pathway has been identified as a critical molecular mechanism driving neuroinflammation, demonstrating specific upregulation in MS patients’ brain tissues and mediating the formation of astrocyte-microglia inflammatory networks (Zelic et al., 2021).